Skip to main content

Advertisement

Table 2 Changes in the platelet chemokine levels in the participants

From: Effects of purified anthocyanin supplementation on platelet chemokines in hypocholesterolemic individuals: a randomized controlled trial

  Placebo (n = 73) Anthocyanins (n = 73) P-valueb
Baseline 12 wk 24 wk Mean change,% (95% CI)a Baseline 12 wk 24 wk Mean change,% (95% CI)a
CXCL7 (ng/ml) 167.63 ± 38.78 165.82 ± 37.83 166.20 ± 31.92 4.22 170.52 ± 44.86 157.76 ± 43.21 138.83 ± 30.49c −12.32 0.011
(−2.33 to 11.05) (−19.25 to −5.00)d
CXCL5 (pg/ml) 159.43 ± 29.35 157.85 ± 31.80 157.32 ± 29.74 1.93 160.40 ± 36.26 150.78 ± 28.98 c 137.61 ± 26.14c −9.95 0.006
(−4.18 to 9.28) (−15.84 to −3.56)d
CXCL8 (pg/ml) 22.97 ± 2.73 22.91 ± 2.51 22.97 ± 4.24 0.66 22.93 ± 1.96 22.32 ± 1.61 c 21.40 ± 1.07c −6.07 0.016
(−2.99 to 4.88) (−8.15 to −4.23)d
CXCL12 (ng/mL) 2.16 ± 0.53 2.15 ± 0.51 2.14 ± 0.46 5.43 2.19 ± 0.56 2.11 ± 0.34 1.86 ± 0.47c −8.11 0.020
(−2.03 to 14.16) (−15.98 to −0.30)d
CCL2 (pg/mL) 504.99 ± 165.34 502.68 ± 157.33 515.76 ± 132.04 12.84 502.97 ± 139.91 476.96 ± 113.74 414.61 ± 87.14c −11.63 0.014
(1.05 to 27.23) (−18.16 to −4.85)d
CXCL4L1 (pg/ml) 124.29 ± 88.87 134.00 ± 69.82 135.16 ± 75.07 0.08 126.52 ± 67.05 126.44 ± 75.21 112.27 ± 86.78 −0.80 0.769
(−0.21 to 0.35) (−2.07 to 0.06)
CXCL1 (ng/ml) 20.96 ± 3.15 21.94 ± 2.38 22.92 ± 3.67 0.07 21.30 ± 4.71 21.00 ± 3.37 21.07 ± 1.79 −0.02 0.529
(−0.06 to 0.19) (−0.24 to 0.16)
PAI-1 (ng/ml) 101.52 ± 41.81 106.13 ± 48.55 108.84 ± 14.31 0.08 104.07 ± 52.84 107.16 ± 36.38 99.62 ± 42.35 −0.44 0.888
(−0.10 to 0.29) (−1.34 to 0.20)
MIF (ng/ml) 32.91 ± 10.02 30.46 ± 9.54 29.51 ± 14.58 −9.90 32.69 ± 13.94 31.26 ± 8.53 26.93 ± 10.56 2.65 0.801
(−25.96 to 7.13) (−32.90 to 39.14)
  1. The data are expressed as the mean ± SD
  2. No significant differences in any variable were observed between the two groups at baseline, as determined using unpaired Student’s t-test
  3. aCalculated as (value at week 24 – value at baseline)/value at baseline × 100
  4. bThe effects of the intervention on these variables were evaluated by repeated-measures ANOVA
  5. c P < 0.05 vs. baseline, as assessed by paired Student’s t-test
  6. d P < 0.05 vs. percentage changes in the placebo group, as assessed by unpaired Student’s t-test